Market Place
Sourcing Support
Palleon Pharma GLIMMER-01 E-602 + Cemiplimab Data at SITC
08 Nov 2024 //
BUSINESSWIRE
MAIA Announces Positive THIO Phase 2 Survival Updates
10 Sep 2024 //
BUSINESSWIRE
Regeneron To Highlight Progress At WCLC And ESMO
09 Sep 2024 //
GLOBENEWSWIRE
Libtayo Demonstrates Durable Survival Benefit In Lung Cancer
09 Sep 2024 //
GLOBENEWSWIRE
MAIA Bio: THIO Efficacy In Non-Small Cell Lung Cancer
04 Jun 2024 //
BUSINESSWIRE
Regn7075 Egfr Costimulatory Combo: With Libtayo® Antitumor At Asco
23 May 2024 //
GLOBENEWSWIRE
ASCO: Regeneron misses mark with one CR in solid tumor trial
23 May 2024 //
FIERCE BIOTECH
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals
08 Jan 2024 //
PR NEWSWIRE
Ankyra Announces Trial Agreement with Regeneron to Evaluate ANK-101
13 Nov 2023 //
BUSINESSWIRE
Libtayo Treatment Demonstrates Encouraging Event-Free Survival in CSCC
21 Oct 2023 //
GLOBENEWSWIRE
OncoNano and Regeneron Enter into Trial Supply Agreement for Use of Libtayo
06 Sep 2023 //
BUSINESSWIRE
Two deaths halt Regeneron’s prostate cancer bispecific antibody trial
05 Aug 2023 //
ENDPTS
BioLineRx Announces Initiation of Phase 2 Trial in First Line Metastatic Pancreatic Cancer
17 Jul 2023 //
PR NEWSWIRE
Palleon Pharma First Patient Dosed with E-602 in Combination with Cemiplimab
22 Jun 2023 //
BUSINESSWIRE
The combination of ISA101b and Libtayo® shows promising results
06 Jun 2023 //
PR NEWSWIRE
ISA Pharmaceuticals to Present First Trial Data from Phase II Study of ISA101b
25 May 2023 //
PR NEWSWIRE
Fianlimab Combined with Libtayo® (cemiplimab) Shows Durable Responses
25 May 2023 //
GLOBENEWSWIRE
EC Approves Cemiplimab Plus Chemotherapy for First-line PD-L1+ NSCLC
30 Mar 2023 //
ONCLIVE
Libtayo secures EMA committee backing for first-line lung cancer
25 Feb 2023 //
PRESS RELEASE
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron
05 Jan 2023 //
GLOBENEWSWIRE
Libtayo Approved in Japan for Advanced or Recurrent Cervical Cancer
23 Dec 2022 //
PR NEWSWIRE
MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe
13 Dec 2022 //
BUSINESSWIRE
Regeneron`s Libtayo Receives Approval in Europe
08 Dec 2022 //
EMA
Regeneron`s Libtayo delivers lung cancer win with BMS` Yervoy
02 Dec 2022 //
FIERCEPHARMA
EC approves Regeneron’s immunotherapy for cervical cancer
23 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
Libtayo (cemiplimab) Approved by the European Commission
22 Nov 2022 //
PRNEWSWIRE
Regeneron Carves Out Bigger Slice of NSCLC Market with New Approval
10 Nov 2022 //
BIOSPACE
Libtayo in with Chemotherapy Approved by FDA as Treatment for NSCLC
09 Nov 2022 //
PRNEWSWIRE
Regeneron`s Biologic Libtayo (Cemiplimab) Receives Approval in the U.S.
08 Nov 2022 //
FDA
Libtayo Receives Positive CHMP Opinion Recommending Approval
14 Oct 2022 //
PRNEWSWIRE
Neoadjuvant Libtayo Monotherapy Data Presented at ESMO and Published in NEJM
12 Sep 2022 //
PRNEWSWIRE
Roche`s VENTANA PD-L1 (SP263) Assay receives CE IVD approval
09 Sep 2022 //
PRNEWSWIRE
Why Regeneron Pharmaceuticals Stock Is Crushing It Today
08 Sep 2022 //
FOOL
OncoResponse Announces Agreement with Regeneron to Evaluate OR2805
07 Sep 2022 //
PRNEWSWIRE
MAIA Biotechnology to Present Design of THIO-101 Trial at ESMO Congress 2022
06 Sep 2022 //
BUSINESSWIRE
ESMO Presentations of Data Showcase Potential of Regeneron`s Oncology Pipeline
04 Sep 2022 //
PRNEWSWIRE
Regeneron expects approval delay of Libtayo plus chemo in NSCLC
04 Aug 2022 //
FIERCEPHARMA
Regeneron Completes Purchase of Sanofi`s Stake in Libtayo® (cemiplimab)
01 Jul 2022 //
PRNEWSWIRE
Regeneron Buys Sanofi Cancer Drug for Up to $1.1 Billion
03 Jun 2022 //
BLOOMBERGLAW
INOVIO Announces Survival Results for INO-5401 + INO-9012 with Libtayo
27 May 2022 //
PRNEWSWIRE
NICE signs off on Libtayo for skin cancer type
27 May 2022 //
FIERCEPHARMA
NICE recommendation for Sanofi and Regeneron’s CSCC treatment
26 May 2022 //
PHARMATIMES
Unable to `align` with FDA, Regeneron, Sanofi pull Libtayo BLA
29 Jan 2022 //
FIERCEPHARMA
FDA Accepts for Review Libtayo + Chemotherapy for Advanced NSCLC
19 Jan 2022 //
PRNEWSWIRE
Sanofi (SNY) CEO Paul Hudson Presents at JPMorgan 40th Annual Healthcare Conference (Transcript)
11 Jan 2022 //
SEEKINGALPHA
BioNTech’s BNT111 to treat advanced melanoma receives FTD by US FDA
22 Nov 2021 //
PHARMABIZ
Libtayo® (cemiplimab) approved in Canada for the first-line treatment
29 Oct 2021 //
NEWSWIRE
Libtayo® (cemiplimab) approved in Canada for locally advanced(BCC)
29 Oct 2021 //
NEWSWIRE
Regeneron, Sanofi post competitive Libtayo data in 1L NSCLC
20 Sep 2021 //
FIERCEPHARMA
ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy
19 Sep 2021 //
PRNEWSWIRE
ISA Pharmaceuticals Starts Third Phase 2 Clinical Trial of ISA101b and Libtayo
07 Sep 2021 //
PRNEWSWIRE
Cervical cancer treatment shake-up diminish Libtayo and balstilimab uptake
20 Aug 2021 //
CLINICALTRIALSARENA
Sanofi, Regeneron announce phase 3 trial of Libtayo in combo with chemotherapy
07 Aug 2021 //
PHARMABIZ
Libtayo is ending a lung cancer phase 3 early on positive data
05 Aug 2021 //
FIERCEPHARMA
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron
07 Jul 2021 //
BUSINESSWIRE
Libtayo Approved by the European Commission for Lung Cancer
26 Jun 2021 //
PR NEWSWIRE
Libtayo Approved by the European Commission for Basal Cell Carcinoma
26 Jun 2021 //
PR NEWSWIRE
Sanofi, Regeneron`s Libtayo cleared for basal cell carcinoma
26 Jun 2021 //
PHARMATIMES
Sanofi: Libtayo® (cemiplimab) approved by the European Commission
25 Jun 2021 //
GLOBENEWSWIRE
Libtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe
24 May 2021 //
PRNEWSWIRE
